Nektar gains on updated response data for NKTR-214

Nektar Therapeutics (NASDAQ:NKTR) added $18.32 (22%) to $102.87 on Friday after President and CEO Howard Robin said that two additional renal cell carcinoma (RCC) patients who previously achieved stable disease have converted to responders

Read the full 346 word article

User Sign In